HSPA5 and pancreatic ductal adenocarcinoma: Previously, HSPA5 is found to negatively regulate the ferroptosis in human pancreatic ductal adenocarcinoma, and the HSPA5-GPX4 pathway could regulate ferroptosis resistance and inhibit the anticancer activity of gemcitabine [23].